These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32384884)

  • 1. Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.
    Levada OA; Troyan AS; Pinchuk IY
    BMC Psychiatry; 2020 May; 20(1):208. PubMed ID: 32384884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diagnostic Value of the Combination of Serum Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 for Major Depressive Disorder Diagnosis and Treatment Efficacy.
    Troyan AS; Levada OA
    Front Psychiatry; 2020; 11():800. PubMed ID: 32922315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
    J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
    Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
    Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
    Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
    Almeida SS; Christensen MC; Simonsen K; Adair M
    J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
    Chokka P; Bougie J; Rampakakis E; Proulx J
    CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
    Christensen MC; Schmidt S; Grande I
    J Psychopharmacol; 2022 May; 36(5):566-577. PubMed ID: 35499104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
    Jacobsen P; Zhong W; Xu R; Nomikos G
    J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
    Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
    Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
    Christensen MC; Sluth LB; McIntyre RS
    J Affect Disord; 2019 Feb; 245():508-516. PubMed ID: 30439678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study.
    McCue M; Sarkey S; Eramo A; François C; Parikh SV
    BMC Psychiatry; 2021 Dec; 21(1):622. PubMed ID: 34895181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Huang IC; Chang TS; Chen C; Sung JY
    Int J Neuropsychopharmacol; 2022 Dec; 25(12):969-978. PubMed ID: 35981958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
    Christensen MC; Schmidt SN; Grande I
    J Affect Disord; 2023 Oct; 338():423-431. PubMed ID: 37315590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis.
    Shi Y; Luan D; Song R; Zhang Z
    Eur Neuropsychopharmacol; 2020 Dec; 41():40-51. PubMed ID: 32980240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.